Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001294

Iodixanol

European Pharmacopoeia (EP) Reference Standard

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C35H44I6N6O15
Numéro CAS:
92339-11-2
Poids moléculaire :
1550.18
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

iodixanol

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62)

Clé InChI

NBQNWMBBSKPBAY-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Iodixanol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1343550

Iodixanol Related Compound D, United States Pharmacopeia (USP) Reference Standard

Y0001292

Iodixanol impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001291

Iodixanol impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001293

Iodixanol impurity H, European Pharmacopoeia (EP) Reference Standard

1343517

Iodixanol, United States Pharmacopeia (USP) Reference Standard

1343540

Iodixanol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1343561

Iodixanol Related Compound E, United States Pharmacopeia (USP) Reference Standard

PHR3015

Iodixanol, pharmaceutical secondary standard, certified reference material

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Hyun-Jung Jang et al.
AJR. American journal of roentgenology, 201(2), 314-321 (2013-07-26)
The purpose of this study was to identify the essential number of phases from multiphasic CT for 1- to 2-cm hepatocellular carcinoma (HCC) on surveillance ultrasound and to compare the results with the American Association for the Study of Liver
Sonja M Kandel et al.
Radiology, 270(1), 125-130 (2013-09-14)
To analyze the effect of the duration of contrast material bolus injection on perfusion values in a swine model by using the maximum slope method. This study was approved by the institutional animal care committee. Twenty pigs (weight range, 63-77
Kartik Jhaveri et al.
AJR. American journal of roentgenology, 201(2), W292-W296 (2013-07-26)
The purpose of this study is to evaluate the interval growth, tumor recurrence, and metastatic disease occurrence of cystic renal cell carcinoma (RCC). Pre-and posttreatment imaging of 47 histologically proven cystic RCCs, with at least 6 months of pretreatment imaging
Erica M Weekman et al.
Journal of neuroinflammation, 11, 127-127 (2014-07-27)
The polarization to different neuroinflammatory phenotypes has been described in early Alzheimer's disease, yet the impact of these phenotypes on amyloid-beta (Aβ) pathology remains unknown. Short-term studies show that induction of an M1 neuroinflammatory phenotype reduces Aβ, but long-term studies
Mauro Maioli et al.
Journal of the American College of Cardiology, 63(14), 1387-1394 (2014-02-18)
The aim of this study was to evaluate the relationship between pre-procedural fluid status assessed by bioimpedance vector analysis (BIVA) and development of contrast-induced acute kidney injury (CI-AKI). Accurate fluid management in patients undergoing angiographic procedures is of critical importance
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique